BioCentury | Sep 26, 2018
Distillery Therapeutics

Cancer

...Next steps could include optimizing and testing the compounds in the models. Heidelberg Pharma AG, Link Health Group...
BioCentury | May 15, 2018
Distillery Therapeutics

Cancer

...a KSP inhibitor, in Phase II testing to treat multiple myeloma (MM). 4SC AG and Link Health Group...
BioCentury | Oct 13, 2016
Distillery Therapeutics

Therapeutics: Ring finger protein 20 (RNF20); RNF40; kinesin spindle protein (KSP; Eg5; KIF11)

...filanesib ( ARRY-520 ) in Phase II testing for multiple myeloma (MM). 4SC AG and Link Health Group...
BioCentury | Jun 6, 2016
Company News

4SC, Link Health deal

...4SC granted Link Health exclusive rights to develop and commercialize 4SC-205 in Taiwan and China, including Hong...
...rights to develop and commercialize 4SC-205 in Taiwan and China, including Hong Kong and Macau. Link Health...
...disclose additional details, and Link Health did not respond to inquiries. 4SC AG (Xetra:VSC), Planegg-Martinsried, Germany Link Health Group...
BioCentury | Jun 1, 2016
Company News

Link gets China rights to 4SC cancer candidate

...4SC AG (Xetra:VSC) granted Link Health Group (Guangzhou, China) exclusive rights to oncology candidate 4SC-205 in China, Hong...
...Guangzhou, China) exclusive rights to oncology candidate 4SC-205 in China, Hong Kong, Taiwan and Macau. Link Health...
...it is seeking other partners for the candidate, and may use clinical data generated by Link Health...
BioCentury | Mar 14, 2016
Politics, Policy & Law

Value demonstration

...side,'" Scott told BioCentury. CMS described outcomes-based risk-sharing agreements as "voluntary agreements with manufacturers to link health...
BioCentury | Jul 14, 2014
Company News

Wilex, RedHill deal

...serine protease inhibitor targeting urokinase-type plasminogen activator ( uPA ). Earlier this year, Wilex granted Link Health Group...
BioCentury | Apr 7, 2014
Company News

Link Health, Wilex deal

...Wilex granted Link Health exclusive rights to develop and commercialize Mesupron in Taiwan and China, including Hong...
...$9.6 million) for the first four indications developed by Link Health, plus staggered medium single-digit royalties. Link Health...
...partners said terms for additional indications are not disclosed. The companies said data generated by Link Health...
Items per page:
1 - 8 of 8
BioCentury | Sep 26, 2018
Distillery Therapeutics

Cancer

...Next steps could include optimizing and testing the compounds in the models. Heidelberg Pharma AG, Link Health Group...
BioCentury | May 15, 2018
Distillery Therapeutics

Cancer

...a KSP inhibitor, in Phase II testing to treat multiple myeloma (MM). 4SC AG and Link Health Group...
BioCentury | Oct 13, 2016
Distillery Therapeutics

Therapeutics: Ring finger protein 20 (RNF20); RNF40; kinesin spindle protein (KSP; Eg5; KIF11)

...filanesib ( ARRY-520 ) in Phase II testing for multiple myeloma (MM). 4SC AG and Link Health Group...
BioCentury | Jun 6, 2016
Company News

4SC, Link Health deal

...4SC granted Link Health exclusive rights to develop and commercialize 4SC-205 in Taiwan and China, including Hong...
...rights to develop and commercialize 4SC-205 in Taiwan and China, including Hong Kong and Macau. Link Health...
...disclose additional details, and Link Health did not respond to inquiries. 4SC AG (Xetra:VSC), Planegg-Martinsried, Germany Link Health Group...
BioCentury | Jun 1, 2016
Company News

Link gets China rights to 4SC cancer candidate

...4SC AG (Xetra:VSC) granted Link Health Group (Guangzhou, China) exclusive rights to oncology candidate 4SC-205 in China, Hong...
...Guangzhou, China) exclusive rights to oncology candidate 4SC-205 in China, Hong Kong, Taiwan and Macau. Link Health...
...it is seeking other partners for the candidate, and may use clinical data generated by Link Health...
BioCentury | Mar 14, 2016
Politics, Policy & Law

Value demonstration

...side,'" Scott told BioCentury. CMS described outcomes-based risk-sharing agreements as "voluntary agreements with manufacturers to link health...
BioCentury | Jul 14, 2014
Company News

Wilex, RedHill deal

...serine protease inhibitor targeting urokinase-type plasminogen activator ( uPA ). Earlier this year, Wilex granted Link Health Group...
BioCentury | Apr 7, 2014
Company News

Link Health, Wilex deal

...Wilex granted Link Health exclusive rights to develop and commercialize Mesupron in Taiwan and China, including Hong...
...$9.6 million) for the first four indications developed by Link Health, plus staggered medium single-digit royalties. Link Health...
...partners said terms for additional indications are not disclosed. The companies said data generated by Link Health...
Items per page:
1 - 8 of 8